Drug Trial Radar · NCT05727397
Efficacy and Safety of RC28-E Versus Aflibercept
Last checked: Nov 19, 2026Latest source record: Aug 31, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
432
Planned (sponsor's estimate)
Start
Mar 14, 2023
Primary completion
Nov 29, 2025
Study completion Dec 29, 2025
Sponsor
- Lead sponsor
- RemeGen Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Feb 14, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, double-masked, multicenter study comparing the the efficacy and safety of RC28-E injection (a chimric decoy receptor trap fusion protein by dual blockage of VEGF and FGF-2) versus aflibercept in patients with wet age-related macular degeneration.
Conditions
- Wet Age-related Macular Degeneration
Interventions
RC28-EDrug
Ophthalmic solution for intravitreal injection administered as a 2.0mg/50 µL dose.
AfliberceptDrug
Ophthalmic solution for intravitreal injection administered as a 2.0mg/50 µL dose.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean change from baseline in BCVA at week 48;Time frame: Baseline, week 48
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing Hospital
Beijing, Beijing Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.